BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29110283)

  • 1. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
    Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Zandieh-Doulabi B; Forouzanfar T; Helder MN
    Int J Nanomedicine; 2018; 13():3853-3866. PubMed ID: 30013340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats.
    Wang JL; Liu YL; Li Y; Dai WB; Guo ZM; Wang ZH; Zhang Q
    Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):7348-57. PubMed ID: 22977140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
    Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
    Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
    Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
    Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
    Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
    Qiu R; Sun D; Bai Y; Li J; Wang L
    Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
    Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
    Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
    Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
    Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Remote Loading of Doxorubicin into DPPC/Poloxamer 188 Hybrid Liposome to Retain Thermosensitive Property and the Assessment of Carrier-Based Acute Cytotoxicity for Pulmonary Administration.
    Tagami T; Kubota M; Ozeki T
    J Pharm Sci; 2015 Nov; 104(11):3824-3832. PubMed ID: 26228287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment.
    Chowdhury N; Chaudhry S; Hall N; Olverson G; Zhang QJ; Mandal T; Dash S; Kundu A
    AAPS PharmSciTech; 2020 Jul; 21(6):202. PubMed ID: 32696338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.
    Patel K; Doddapaneni R; Sekar V; Chowdhury N; Singh M
    Mol Pharm; 2016 Jun; 13(6):2049-58. PubMed ID: 27070720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
    Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
    Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane-Loaded Doxorubicin Liposomes Based on Ion-Pairing Technology with High Drug Loading and pH-Responsive Property.
    Xu H; Zhang L; Li L; Liu Y; Chao Y; Liu X; Jin Z; Chen Y; Tang X; He H; Kan Q; Cai C
    AAPS PharmSciTech; 2017 Aug; 18(6):2120-2130. PubMed ID: 28028795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
    Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z
    ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
    Liu Z; Tao Z; Zhang Q; Wan S; Zhang F; Zhang Y; Wu G; Wang J
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):687-695. PubMed ID: 29392452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
    Li Y; Hou H; Zhang P; Zhang Z
    Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.